Kang Min-Hee, Lee Jaeil, Kim Sang-Ki, Koh Kyeyoung, Kang Mi-Ae, Park Hee-Myung
Department of Bio-animal Health, Jangan University, Gyeonggi-do, Republic of Korea.
Biomaterial R&BD Center, VaxCell-Bio, Gwangju, Republic of Korea.
Front Vet Sci. 2025 Jun 9;12:1603421. doi: 10.3389/fvets.2025.1603421. eCollection 2025.
This study investigated the safety and therapeutic potential of recombinant canine interleukin-15 (rcIL-15) as an adjunct to surgical excision in dogs with mammary gland tumors (MGTs). Sixty-one client-owned dogs were initially enrolled, and 55 completed the 12-week study. Dogs were assigned to a test group receiving rcIL-15 with surgery or a control group undergoing surgery alone. RcIL-15 was administered intravenously at 20 μg/kg/day for two 4-day cycles, separated by a 10-day rest period. Clinical monitoring included physiological assessments, blood tests, and owner-reported quality of life (QoL) questionnaires. No significant adverse changes were observed in hematological, biochemical, or physiological parameters. RcIL-15 was well tolerated, with only mild and self-limiting gastrointestinal signs and injection site reactions. Dogs in the rcIL-15 group showed significantly improved QoL, particularly in pain, appetite, and activity. Notably, serum C-reactive protein levels decreased over time in the rcIL-15 group, suggesting reduced systemic inflammation. VEGF levels remained stable in the test group but increased in controls, while IFN- concentrations rose significantly following rcIL-15 treatment, indicating immune activation. These findings suggest that rcIL-15 may enhance antitumor immunity and alleviate tumor-related inflammation without compromising safety. The combination of surgery and rcIL-15 improved clinical outcomes compared to surgery alone, supporting its use as a novel immunotherapeutic adjunct for canine MGTs. However, limitations include the short follow-up period and lack of cellular immune profiling. Further studies with longer follow-up and immunological assessment are warranted to confirm these results and explore the broader application of rcIL-15 in veterinary oncology.
本研究调查了重组犬白细胞介素-15（rcIL-15）作为乳腺肿瘤（MGT）犬手术切除辅助治疗的安全性和治疗潜力。最初招募了61只客户拥有的犬，55只完成了为期12周的研究。犬被分配到接受rcIL-15联合手术的试验组或仅接受手术的对照组。rcIL-15以20μg/kg/天的剂量静脉注射，共两个4天周期，中间间隔10天休息期。临床监测包括生理评估、血液检查和主人报告的生活质量（QoL）问卷。在血液学、生化或生理参数方面未观察到显著的不良变化。rcIL-15耐受性良好，仅出现轻微的自限性胃肠道症状和注射部位反应。rcIL-15组的犬生活质量显著改善，尤其是在疼痛、食欲和活动方面。值得注意的是，rcIL-15组血清C反应蛋白水平随时间下降，表明全身炎症减轻。试验组VEGF水平保持稳定，而对照组升高，同时rcIL-15治疗后IFN浓度显著升高，表明免疫激活。这些发现表明，rcIL-15可能增强抗肿瘤免疫力并减轻肿瘤相关炎症，同时不影响安全性。与单纯手术相比，手术联合rcIL-15改善了临床结果，支持其作为犬MGT新型免疫治疗辅助药物的应用。然而，局限性包括随访期短和缺乏细胞免疫分析。有必要进行更长时间随访和免疫评估的进一步研究，以证实这些结果并探索rcIL-15在兽医肿瘤学中的更广泛应用。
